Ipca Laboratories Limited (NSE:IPCALAB)
India · Delayed Price · Currency is INR | Market Cap | 499.42B +49.9% |
| Revenue (ttm) | 101.26B +10.6% |
| Net Income | 13.10B +68.2% |
| EPS | 51.63 +68.2% |
| Shares Out | 253.70M |
| PE Ratio | 38.13 |
| Forward PE | 31.47 |
| Dividend | 6.00 (0.31%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 176,431 |
| Open | 1,975.80 |
| Previous Close | 1,970.90 |
| Day's Range | 1,958.40 - 1,995.00 |
| 52-Week Range | 1,251.60 - 2,001.50 |
| Beta | 0.05 |
| Analysts | Strong Buy |
| Price Target | 1,972.28 (+0.41%) |
| Earnings Date | Nov 6, 2026 |
About Ipca Laboratories
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/pro... [Read more]
Financial Performance
In fiscal year 2026, Ipca Laboratories's revenue was 96.47 billion, an increase of 7.90% compared to the previous year's 89.41 billion. Earnings were 11.41 billion, an increase of 54.69%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IPCALAB stock is "Strong Buy." The 12-month stock price target is ₹1,972, which is an increase of 0.41% from the latest price.
News
Ipca Laboratories Transcript: Q1 26/27
Revenue grew 21% year-over-year with strong gains in domestic, export, and API segments, and EBITDA margin improved to 22.88%. FY27 guidance was raised to 14%-16% revenue growth and 23% EBITDA margin, with major CapEx planned for capacity and biotech expansion.
Ipca Laboratories Quarterly report: Q1 2027
Ipca Laboratories has published its Q1 2027 quarterly earnings report on August 14, 2026.
Meet Premchand Godha: Amitabh Bachchan's CA behind a Rs 28,000cr giant
Premchand Godha's success story is one of India's most remarkable business journeys. Long before he became a billionaire businessman, Godha worked as the Chartered Accountant (CA) for Amitabh Bachchan...
Ipca Laboratories Creates History with GUINNESS WORLD RECORDS™ Title for ACNE-UV Gel by Creating "Largest Card Board Box Sentence"
Business Wire IndiaIpca Laboratories created history recently by securing a GUINNESS WORLD RECORDS™ title for ACNE-UV Gel through the creation of the "Largest Cardboard Box Sentence" at the iconic Jio...
Ipca Laboratories secures global licensing agreement for novel biologics delivery
Ipca Laboratories Ltd. and Bhami’s Research Laboratory (BRL) have announced a global licensing agreement granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery pl...
Ipca Laboratories Transcript: Q4 25/26
Q4 FY26 saw 12% domestic growth and 8% consolidated revenue growth, with EBITDA margins exceeding guidance. FY27 outlook is for 12%-13% revenue growth and margin improvement, despite raw material and freight cost pressures.
Ipca Laboratories Quarterly report: Q4 2026
Ipca Laboratories has published its Q4 2026 quarterly earnings report on June 1, 2026.
Ipca Laboratories Annual report: Q4 2026
Ipca Laboratories has published its Q4 2026 annual report on June 1, 2026.
Ipca Laboratories to hold Q4FY26 earnings call on June 1, 2026
Ipca Laboratories has scheduled a conference call to discuss its fourth quarter fiscal 2026 (Q4FY26) earnings and provide a business update. The call is set for Monday, 1st June 2026,…
Top stocks to buy: Stock recommendations for March 30, 2026 week - check list
Stock market recommendations: Ipca Laboratories, and AU Small Finance Bank are the stocks that Motilal Oswal Wealth Management Research Desk recommends buying for the week starting March 30, 2026. Tar...
Top stocks to buy: Stock recommendations for March 23, 2026 week - check list
Stock market recommendations: Ipca Laboratories, and Hindalco are the top stocks that Motilal Oswal Wealth Management Research Desk has picked for this week starting March 23, 2026.
Ipca Laboratories Transcript: Q3 25/26
Q3 saw 6.5% revenue growth and improved EBITDA margins, with strong domestic and export performance, especially in chronic therapies and West Africa. Unichem margins remain under pressure but are expected to recover as new launches and filings mature.
Ipca Laboratories Quarterly report: Q3 2026
Ipca Laboratories has published its Q3 2026 quarterly earnings report on February 16, 2026.
Ipca Laboratories Q3 Results: Net profit jumps 31.5% YoY to Rs 326.27 crore, revenue up 6.55%
Ipca Laboratories reported a steady performance for the quarter ended December 31, 2025, with profit growth outpacing revenue expansion on...
Ipca Laboratories receives US FDA VAI status for Tarapur API facility
Ipca Laboratories has received a positive regulatory update from the United States Food and Drug Administration (US FDA) for its...
This brokerage firm advises to Buy IPCA Labs shares and expects nearly 20% upside in stock price
Emkay Global has initiated coverage on Ipca Laboratories with a buy rating and a target price of ₹1,700 per share,...
Ipca Laboratories Transcript: Q2 25/26
Domestic and API businesses delivered strong growth, with EBITDA margins improving year-over-year. Export formulations declined but are expected to recover in H2, while Unichem's performance is stabilizing post-restructuring. R&D spend is rising, supporting a robust pipeline.
Ipca Laboratories Quarterly report: Q2 2026
Ipca Laboratories has published its Q2 2026 quarterly earnings report on November 13, 2025.
Ipca Laboratories Q2 FY26 results: Revenue up 9% YoY to Rs 2,556.5 crore, Net profit rises 23%
Ipca Laboratories Ltd reported a 9% year-on-year growth in revenue from operations at Rs 2,556.50 crore for Q2 FY26, compared...
Ipca and BioSimilar Sciences sign Technology Transfer Agreement for next-gen cancer and anti-inflammatory biosimilar
Ipca Laboratories Ltd. (NSE: IPCA) and BioSimilar Sciences PR LLC (BSS) today announced a definitive Technology Transfer and Joint Development Agreement. As part of the deal, the late-stage developmen...
Ipca Laboratories Transcript: Q1 25/26
Domestic and export businesses delivered double-digit growth, with strong gains in chronic and acute segments. Standalone margins improved, but consolidated EBITDA margin guidance was trimmed due to Unichem's challenges, including one-time provisions and market share losses.
Ipca Laboratories Quarterly report: Q1 2026
Ipca Laboratories has published its Q1 2026 quarterly earnings report on August 12, 2025.
Ipca Laboratories Q1 results: Net profit surges 21% YoY to Rs 233.21 crore, revenue up 10.3%
Ipca Laboratories Limited posted a consolidated net profit attributable to owners of the company at Rs 233.21 crore for the quarter ended June 30, 2025, marking a 21% increase from Rs 192.24 crore in ...
Top Q1 results today, August 11: SJVN, BEML, Bata India, Titagarh Rail, Ipca Laboratories and more to announce earnings
The earnings season continues to heat up as Monday, August 11, 2025, will see a busy line-up of companies reporting their financial results for the first quarter of FY26. From large-cap names to mid a...
IPCA Laboratories shares dip over 2% after HSBC cuts target price to Rs 1,330
IPCA Laboratories Ltd. shares fell more than 2% in early trading following HSBC’s downgrade of the stock’s target price to ₹1,330 per share. The brokerage maintained a Hold rating on the stock, reflec...